One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin.

G. Lippi,M. Franchini,E. Favaloro

DOI: https://doi.org/10.1097/MBC.0B013E32831BC324

Abstract:The mainstay in the treatment of haemophilia A is replacement therapy with factor VIII (FVIII) [1]. Recently, the risk of pathogen transmission via repeated infusions of plasma-derived FVIII (pd-FVIII) concentrates has been consistently lowered through risk reduction strategies for pd-FVIII therapies by better donor selection and more vigorous antiviral treatments and the introduction of recombinant clotting factors for haemophilia, beginning with recombinant factor VIII (rFVIII) in 1992 [2]. Recent research has been directed towards overcoming the inherent limitations of rFVIII expression and the inhibitor response, including improved biosynthesis and secretion of recombinant products, functional activity, half-life and antigenicity/ immunogenicity. Strategies that have been successful for other therapeutic proteins are now being applied to FVIII, producing structurally modified proteins by addition of polyethylene glycol (PEG) polymers and polysialic acids and alternative formulation with PEGmodified liposomes [3]. The approaches to improve the yield of rFVIII in cell culture systems, allowing production of rFVIII at industrial scale, thus, meeting the growing demand for this safer product, also include genetic engineering of B-domain-deleted FVIII (BDD-rFVIII) [4,5]. Some of these proteins are already available in the market and have been utilized in gene therapy strategies [6], including ReFacto, a BDDrFVIII, monoclonal antibody-purified, solvent-detergent-treated factor VIII with no albumin added to the final formulation [7]. Despite these remarkable advances in therapy, clinical laboratories are now faced with the challenge of providing reliable, accurate and meaningful FVIII assessment in patients receiving repeated or continuous infusions of rFVIII, especially BDD-rFVIII.